Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
出版年份 2022 全文链接
标题
Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-03-08
DOI
10.3389/fimmu.2022.797589
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
- (2021) Wilfredo F. Garcia-Beltran et al. CELL
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
- (2021) Xuping Xie et al. NATURE MEDICINE
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
- (2021) Kai Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2
- (2021) Donald J. Benton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
- (2021) Maria G. Noval et al. Scientific Reports
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
- (2021) Chihiro Motozono et al. Cell Host & Microbe
- Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants
- (2021) Angela Choi et al. JOURNAL OF VIROLOGY
- Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
- (2021) Matthias Tenbusch et al. LANCET INFECTIOUS DISEASES
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
- (2021) Galit Alter et al. NATURE
- BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
- (2021) Jianying Liu et al. NATURE
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- (2021) Joana Barros-Martins et al. NATURE MEDICINE
- Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
- (2021) Dan H. Barouch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
- (2021) Takuya Tada et al. mBio
- The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance
- (2021) Izumi Kimura et al. Cell Reports
- Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
- (2020) Tyler N. Starr et al. CELL
- Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
- (2020) Hongjing Gu et al. SCIENCE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2
- (2020) Takuya Tada et al. Cell Reports
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started